Menu

CME Corner

Program Detail

Release Date: June-24-16
Credit Expiration Date: June-24-17

Faculty

Carol H. Wysham, MD, FACP, FACE
Clinical Associate Professor of Medicine
University of Washington School of Medicine
Section Head, Rockwood Center for Diabetes and Endocrinology
Rockwood Clinic
Spokane, WA

 

Credit Hours

0.5 AMA PRA Category 1 Credit

Medium

Mobile + Online on QuantiaMD

Program Description

The management of T2DM remains a major challenge as many patients continue to struggle with achieving glycemic control. Glucagon-like peptide 1 (GLP-1) receptor agonists, one of the newer drug classes for the treatment of T2DM, have been shown to be safe and effective in improving glycemic control. This activity will examine the use of GLP-1 receptor agonists in clinical practice, including long-term benefits and risks and their optimal role as monotherapy and in combination with other therapies.

Program Developer/Facilitator


.

Target Audience

This educational activity is designed to meet the needs of primary care physicians and other clinicians who diagnose and manage patients with type 2 diabetes.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Explain the clinical implications of glycemic variability in patients with T2DM.
  2. Outline differences among T2DM therapies regarding their effects on glycemic targets.
  3. Describe the effects of GLP-1 receptor agonists on glycemic targets, including A1c, fasting glucose, and postprandial glucose.

Disclosures

Carol H. Wysham, MD, FACP, FACE, has disclosed the following:
Consultant: AstraZeneca, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Inc., Sanofi Aventis US, LLC
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi Aventis US, LLC
Research/Grant Support: AstraZeneca, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Inc., Merck, Novo Nordisk, Sanofi Aventis US, LLC

Rick Ricer, MD, Physician Reviewer, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, University of Cincinnati, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education has no conflicts of interest to disclose.

The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports their presentation will not contain reference to investigational and/or off-label uses.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release date: June 24, 2016
Last review date: June 24, 2016
Expiration date: June 24, 2017

Commercial Support Statements

This activity is supported by educational grants from Novo Nordisk and Lilly. 

Instructions

Completion Instructions

  1. Accessing Activity:
    * Click "Start Program" and log into program on QuantiaMD.com
    * Take the pre-test
    * Review the activity
    * Take the post-test and score 80%
    * You are allowed a total of 3 attempts
    * Complete the evaluation
    * View, print, or save a CME certificate verifying your
    credit/participation in this activity
  2. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

There is no charge for CME credit.

Disclaimer

© 2016 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, Novo Nordisk, or Lilly. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS